New Secondary Analysis of Phase 3 Data Demonstrates Sotagliflozin Improves Time-In-Range (TIR) and Several Parameters of Glucose Control and Variability in Basal Insulin-Treated Type 2 Diabetes

Stock Information for Lexicon Pharmaceuticals Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Lexicon Pharmaceuticals Inc.

Lexicon Appoints Scott Coiante as Chief Financial Officer
Lexicon Announces Receipt of Complete Response Letter for Zynquista(TM) (sotagliflozin)
Lexicon Announces Completion of Enrollment in Phase 2B PROGRESS Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP)
Lexicon Pharmaceuticals to Participate in December Investor Conferences
Lexicon to Reposition as Clinical Development-Focused Company Following Regulatory Update From FDA
Lexicon Appoints Ivan H. Cheung to Board of Directors
Lexicon to Present Phase 3 Trial Design for Sotagliflozin in Hypertrophic Cardiomyopathy (HCM) at Upcoming Medical Congress
Lexicon Pharmaceuticals Announces Departure of President and Chief Operating Officer

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.